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It is known that prenatal exposure to pollutants and particularly heavy metals can 
have long term damaging consequences on infants, due to their accumulation in-
body. Since the 1990s, ten million tonnes of waste have been illegally dumped in 
the area around Caserta and Naples. Thus, direct exposure to waste and heavy 
metals during the last two decades was very frequent in the so-called “Lands of 
fires”. The number of children suffering from cancer and of malformed fetuses in 
Italy's "Land of Fires", an area where toxic waste has been dumped by the mafia, is 
reported significantly higher than elsewhere in the country. In this thesis we 
examined the proteome of the umbilical cords from malformed fetuses obtained by 
therapeutic abortions, after mothers' being exposed to the pollution on “land of fire” 
during early pregnancy, and analyzed the differences between umbilical cords from 
malformed fetuses to healthy ones. The main goals were to understand the impact 
of the contamination by heavy metals on the fetus development, and to identify new 
putative biomarkers of exposure to metal contaminants.  
All umbilical cords were obtained in Campania region (Naples and Caserta, mainly 
in the “land of fires”). The collection of the biological samples was carried out in 
collaboration with the Caserta Hospital “Sant’Anna e San Sebastiano” and with the 
Avellino Hospital “San Giuseppe Moscati”. A proteomic approach based on Filter-
Aided Sample Preparation (FASP) method was set up and performed. This bio-
analytical strategy combines the advantages of in-gel and in-solution digestion for 
mass spectrometry–based proteomics, greatly reduces the time required for sample 
preparation and enables more flexibility in sample processing. Protein identification 
and quantification were performed by matching mass spectrometry data in on-line 
protein database, using the MaxQuant 1.5.2.8 software. Statistical analyses were 
employed to identify proteins whose levels were sensibly different in the umbilical 
cords from malformed fetuses. Gene Ontology (GO) classification was used in 
order to obtain functional information of the differentially expressed proteins and to 
correlate them to the embryonic development. Finally, Matrix Metalloproteinases 
(MMPs) have been shown to play significant roles in a number of physiological 
processes, including embryogenesis and angiogenesis, but they also contribute to 
the development of pathological processes. Thus, gelatin zymography technique 
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was performed to detect MMPs enzymatic activity in the umbilical cords. Our 






















1.1 Metal contamination and fetal malformations 
Despite the last decades of the XX century have been characterized from the 
accelerated technological innovation and the improvement of industrial implants, 
production activities continue to have a profound effect on the quality of the several 
environmental matrices (air, water and land). The risk for the population increases 
in function of proximity to contaminated sites and the risks associated with the 
contamination by heavy metals are particularly significant (Baibergenova et al., 
2003; Zheng et al., 2012). The metal contamination has the capacity to affect the 
reproductive health, as observed both in industrial contests and in war zones where 
weapons containing toxic/carcinogenic and teratogenic metals have been used 
(Suarez et al., 2007; Araneta et al., 2003). The feature of metals, in fact, is to be 
"long-term teratogenic," since they remain in soil or water, accumulate over time in 
tissues of living organisms and the bio-accumulation increases their dangerousness, 
also due to possible synergism of contamination by more metals. The metal 
contamination has the potential to produce malformations and many of the metals 
which are not micro-nutrients, and some micro-nutrients at high concentrations, 
have shown teratogenic, mutagenic, and carcinogenic capacities (Apostoli and 
Catalani, 2011). Most of the so-called congenital malformations determine great 
alterations of the body structures and of the organs functionality, sometimes 
incompatible with the life but very often that allow a life with many limitations and 
determine a serious weight on the affected individuals and on their families. Not 
much is known about these malformations (which all together are in Italy between 
1% and 4% of newborns), neither about the reasons nor about the modalities 
whereby they occur in the organism. For many malformations a single gene that 
determines them isn’t known, in a few cases more genes involved in the 
malformation have identified, in most cases it is believed that are complex events 
susceptible to the influence of the external environment on the mother and/or 
directly on the fetus (Mattison, 2010). 
Epidemiological studies associated with chemical and biochemical analyses, 
conducted in war zones and in particular in the Gaza Strip (Figure 1.1), have shown 
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the existence of a correlation between heavy metal contamination and increased 
reproductive damage, in particular an increase of fetal malformations (Naim et al., 
2012). In the Gaza situation, various pieces of information useful to investigate this 
link were published. In recent times “metal augmented” ammunitions were 
developed and used in the wars and attacks in this century. Indeed, modern 
weapons contain within them not small amounts of powders of metals, such as Cd, 
Pb, Al, U, Hg, Co, V, W (Skaik et al., 2010). Most metals persist in time in the 
environment and many of them accumulate in the bodies, suggesting that dispersion 
of metal powders in the environment may have both immediate and long term 
effects on reproductive health and cancers (Vidosavljević et al., 2013; Jergovic et 
al., 2010). By proving the fact of the presence in tissues at the site of different types 
of wounds of a specific metal signature different for each kind of physical damage 
caused by weaponry it was shown that teratogens and fetotoxicant metal 
contaminants (Pb, U, Al, Ti, Cu, Sr, Ba, Co, Hg, V, Cs and Sn) were delivered by 
weapons in the attacks in the summer of 2006 and during Operation Cast Lead in 
the winter of 2009 (Skaik et al., 2010). Teratogens were also detected in examined 
large bomb craters from 2006 and 2009 bombings (Manduca et al., 2014). 
Reconstructing the reproductive history of women delivering healthy children in 
2011 at Al Shifa Hospital in Gaza, it was reported that the prevalence of birth 
defects has increased in Gaza since 2005, following introduction of air-delivered 
weaponry (Naim et al., 2013). A recent study (Naim et al., 2012) reported highly 
significant correlations between exposure of parental couples to metal delivering 
weaponry during Operation Cast Lead, the major recent military attack up to then, 
and the delivery of a baby with major structural birth defects. The progeny with 
birth defects was conceived 22–26 months after exposures. This information is 
consistent with weaponry being a source of contamination by teratogenic and 
toxicant metals for the population, and suggest association between reproductive 
damage, and exposure to attacks (Manduca et al., 2014). Studies carried out by an 
international team in another post-war context (Fallujah area, Iraq; Figure 1.1) have 
shown, at a distance of 5 and 6 years respectively from war events of 2004-2005, 
persisting hair contamination by metals in adult and children hair, and an increase 
of cases of birth defects documented with a high frequency in 2011 (Alaani et al., 

















Figure 1.1. Gaza Strip and Fallujah area, Iraq. Concerns from professionals have pointed to 
increases in birth defects and cancers in these areas during the years following wars. 
 
In the Campania region, where since the 80s several toxic wastes have been 
"deposited" legally and illegally, observations have been reported that suggest the 
accumulation of these materials has produced an increase of some kinds of diseases, 
such as allergies, cancers, adverse effects on reproductive health (infertility, 
malformations, low birth weight, stillbirths) (Martuzzi et al., 2009). Several studies 
have reported an accumulation of heavy metals in vegetables and in fishes sampled 
in areas of Caserta, Aversa and Phlegraean Fields, which exceeded the regulatory 
limits. Moreover, studies performed on soil samples collected in areas with high 
potential of pollution have shown the presence of concentrations higher than 
normal levels of these metals (Cu, V, Cr, Cd, Pb) (Imperato et al., 2003). Therefore 
the alimentary way, as well as the respiratory one, are considered to cause exposure 
and accumulation of metals in the exposed population. In addition, other 
teratogenic contaminants such as dioxins have been found in the milk of mothers in 
this area (Giovannini et al., 2014). The metals and dioxins have the potential to 
affect the health of the population not only in the exposed generation, but also in 
their offspring. Therefore in-depth studies are needed to understand what factors 
16 
 
and what biochemical and physiological mechanisms are the basis of outbreaks of 
fetal malformations and possibly to limit their incidence. 
 
1.2 “Omics” technologies and environmental proteomics (ecotoxicoproteomics) 
Ecotoxicology is the study of the interactions between living organisms, their 
ecosystems and stressors (Dowling and Sheehan, 2006). The grand goal of 
ecotoxicology in the post-genome era is to characterize the entire set of genes and 
proteins that are affected when humans are exposed to environmental xenobiotics 
(Mussali-Galante et al., 2013). Therefore, a new trend in ecotoxicology and 
biomedical research is the application of so-called “omics” technologies. ‘Omics’ 
technologies adopt a holistic view of the molecules that make up a cell, tissue or 
organism. They are aimed primarily at the universal detection of genes (genomics), 
mRNA (transcriptomics), proteins (proteomics) and metabolites (metabolomics) in 
a specific biological sample in a non-targeted and non-biased manner. This can also 
be referred to as high-dimensional biology; the integration of these techniques is 




Figure 1.2. The “Omics” approach. “Omics” technologies can be used to gain a “system-wide” 
understanding of many important biomedical processes. 
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Genomics is the systematic study of an organism’s genome. The genome is the total 
DNA of a cell or organism. The human genome contains 3.2 billion bases and an 
estimated 30 000–40 000 protein-coding genes (Baltimore, 2001). Traditionally, 
genes have been analyzed individually but microarray technology has advanced 
substantially in recent years. DNA microarrays measure differences in DNA 
sequence between individuals and the expression of thousands of genes can be 
analyzed simultaneously (Horgan and Kenny, 2011). 
The transcriptome is the total mRNA in a cell or organism and the template for 
protein synthesis in a process called translation. The transcriptome reflects the 
genes that are actively expressed at any given moment (Horgan and Kenny, 2011). 
The proteome is defined as the set of all expressed proteins in a cell, tissue or 
organism (Theodorescu and Mischak, 2007). Contrary to genome, the proteome is 
highly dynamic and changes continuously as a response to numerous intra and 
extracellular signaling (Barrett et al., 2005). The proteome is a dynamic reflection 
of both genes and the environment and is thought to hold special promise for 
biomarker discovery because proteins are most likely to be ubiquitously affected in 
disease and disease response (Rifai et al., 2006). Proteomics can be more broadly 
defined as “the effort to establish the identities, quantities, structures, and 
biochemical and cellular functions of all proteins in an organism, organ, or 
organelle, and how these properties vary in space, time, and physiological state” 
(Kenyon et al., 2002). Proteomics is closer to physiology than genomics because 
post-translational regulation of proteins can reduce the correlation between mRNA 
abundance and protein activity (Lemos et al., 2010). Proteomics aims to 
characterize information flow within the cell and the organism, through protein 
pathways and networks (Petricoin et al., 2002), with the aim of understanding the 
functional relevance of proteins (Vlahou and Fountoulakis, 2005). It is complicated 
by its domain size (>100 000 proteins) and the inability to detect accurately low-
abundance proteins.  
Metabolomics can generally be defined as the study of global metabolite profiles in 
a system (cell, tissue or organism) under a given set of conditions (Goodacre et al., 
2004). The metabolome is the final downstream product of gene transcription and, 
therefore, changes in the metabolome are amplified relative to changes in the 
transcriptome and the proteome (Urbanczyk-Wochniak et al., 2003). 
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Snape et al. (2004) proposed the term “ecotoxicogenomics” to describe the 
integration of genomics (transcriptomics, proteomics, and metabolomics) into 
ecotoxicology, and defined it as “the study of gene and protein expression in non-
target organisms that is important in responses to environmental toxicant 
exposures.” 
Specifically for metal exposure assessment, very recently, “metallomics” has 
emerged as a new sub-discipline of toxicogenomics, which investigates the 
interrelationships of metal-induced proteome and metabolome changes. In this 
regard, searches for genes encoding metal-responsive proteins could be interesting 
targets for reporter genes fusions in biomarker establishing (Haferburg and Kothe, 
2010). 
Among “omics” technologies, environmental proteomics or ecotoxicoproteomics 
has become a powerful tool for generating hypotheses regarding how the 
environment affects the biology of non-target organisms. With its rapidly 
expanding analytical tools, it provides a means to study the changes occurring at the 
level of the proteome in response to both the external environment and ontogenetic 
events in animals, plants, and bacteria. 
The approach has obvious applications to ecotoxicology since it has the potential 
both to identify previously unknown protein biomarkers and to gain insights into 
toxicity mechanisms. Since the proteome is a dynamic quantity, it holds out the 
promise of detecting subtle changes in sentinel species as they adapt to altered 
surroundings. 
In the toxicological sciences, the possibility to assess the proteome is a gigantic step 
since the proteomic profiles embody the link between effects at both the molecular 
level and the whole organism level, given that proteins are the first functional stage 
directly or indirectly affected by toxicants (Kovacevic et al., 2009). Therefore, 
more and more researchers are directing their efforts towards proteomic studies and 
have demonstrated the utility of proteomics in the ecotoxicological field. Recent 
studies have demonstrated that ecotoxicoproteomics allows the identification of the 
molecular events involved in toxicant responses and to generate hypotheses on the 
mode of action of stressors with a high potential for identifying novel biomarkers 
(Dowling and Sheehan, 2006; López-Barea and Gómez-Ariza, 2006; Monsinjon 
and Knigge, 2007). 
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1.3 Biomarkers for metal toxicity 
Proteomics is one of the most powerful tools for the identification of molecules 
(biological markers or biomarkers) that place in evidence the exposure of organisms 
to a stressor. A biomarker is a measurable indicator of a specific cellular, 
biochemical or molecular parameter that show whether a key organism has been 
exposed to a stressor (van Ommen et al., 2009). The use of biomarkers has been 
proposed as a sensitive early warning tool for biological effect measurement in 
environmental quality assessment (Cajarville et al., 2000). 
In the last 5 years, an increasing interest towards biomarkers of heavy metals have 
been recorded. The interest in biomarkers for heavy metals impact was defined 
parallels to the development of biomonitoring program, according to the test subject 
either had been exposed in the past or currently exposed to environmental stimuli 
(Sabullah et al., 2015).  
A variety of molecules, such as hormones (Zaccaroni et al., 2009), enzymes such as 
cytochromes  P450 (CYP), cholinesterase, catalase (CAT), glutathione S-transferase 
(GST) (Menezes et al., 2006; Howcroft et al., 2009) and other proteins such as 
vitellogenin, Hsp, etc. and even organelles (Ortiz-Zarragoita and Cajaraville, 2006) 
have been selected as biomarkers of specific chemicals or classes of chemicals 
(Porte et al., 2006). Metabolic enzymes such as aspartate aminotransferase (ASAT), 
alanine aminotransferase (ALAT), superoxide dismutase (SOD), and GST had 
significantly increase in the activity induced by the presence of toxicant especially 
heavy metals (Singh et al., 2012; Saliu and Bawa-Allah, 2012; Han et al., 2013). 
Biomarkers of oxidative stress based on antioxidant enzymes such as SOD, GST, 
CAT, and glutathione peroxidase (GPX) have been utilized to determine the 
toxicity level of metal ions in aquatic organisms and have been proved to be 
sensitive (Radi and Matkovics, 1988; Lopes et al., 2001; Farombi et al., 2007). 
Much of the work in the area of biomarkers has focused on metallothioneins or 
metallothionein-like proteins (MT). These low-molecular weight, cysteine-rich 
metal-binding proteins are reported to play a key role in the binding and transport 
of various metals (Costa et al., 2008, 2009). MT are modulated by heavy metals, 
being an informative and specific biomarker of chronic heavy metal exposure 
(Mussali-Galante et al., 2013).  
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A general mechanism of carcinogenicity of arsenic (As), cadmium (Cd), cobalt 
(Co), and nickel (Ni) seems to be the inhibition of DNA repair enzymes, which 
include the mammalian XPA protein, the bacterial Fpg protein and the poly (ADP-
ribose) polymerase. Specifically, the Fpg protein is inhibited by Cd, copper (Cu), 
and mercury (Hg) and Ni and Co inhibit DNA binding of XPA (Asmuss et al., 
2000). Also, poly (ADP-ribose) polymerase is inhibited by arsenite in mammalian 
cells (Hartwig et al., 2002; Schoen et al., 2004). These proteins have been used as 
biomarkers to analyze response to toxic metals. Trace metals are reported to 
regulate the expression of CYP as well as heavy metals like Hg and lead (Pb) (Ki et 
al., 2009). Apolipoprotein E (Apo E) genotyping has been investigated as an 
indicator of susceptibility to Hg neurotoxicity (Godfrey et al., 2003). Gundacker et 
al. (2007) analyzed the relationship between polymorphisms in GST genes in 
individuals exposed to Hg. Pb inhibits several enzymes in heme formation pathway, 
including delta-aminolevulinic acid dehydratase (ALAD), coproporphyrinogen 
oxidase and ferrochelates. Because Pb effectively inhibits ALAD activity, resulting 
in accumulation of ALA in blood and urine, urinary ALA has also been used as a 
biomarker for Pb exposure or a marker of early biologic effect of Pb (Sithisarankul 
et al., 1998). The activities of pyrimidine nucleotidase and nicotinamide adenine 
dinucleotide synthetase in blood are decreased in Pb exposure. These can also be 
useful biomarkers of effect in humans (Sakai, 2000). It is suggested that Vitamin D 
receptor (VDR) may be playing a role in susceptibility to Pb accumulation (Onalaja 
and Claudio, 2000). Neurobehavioral changes due to Pb exposure have been 
associated with Apo E genotype (Stewart et al., 2002; Godfrey et al., 2003).  
MT binds Cd strongly and is considered a good biomarker of Cd exposure (Kakkar 
and Jaffery, 2005). Effect biomarkers of Cd-induced renal dysfunction are β2-
microglobulin, retinol binding protein and albumin (Jin et al., 2002). α1-
Microglobulin is shown to be a promising marker of Cd-induced tubular 
dysfunction, possibly better than β2-microglobulin (Moriguchi et al., 2004). 
Elevation in enzymes primarily of renal tubular origin, such as N-acetyl-β-D-
glucosaminidase (NAG) and alanine aminopeptidase (AAP), has been associated 
with occupational Cd exposure (Lauwerys et al., 1994). Cd combined with As may 
have additive effect on renal dysfunction in workers exposed to both metals. 
Positive correlations and significant dose–effect have been reported by Hong et al. 
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(2003) among the concentrations of urinary Cd, As and levels of β2-microglobulin, 
albumin, N-acetyl-β-D-glucosaminidase. Studies concerning the effects of 
polymorphic forms of arsenic methyl-transferase (AsMT) in regulating the toxicity 
of AsIII in mice (Stýblo et al., 2002; Aposhian et al., 2004; Wang et al., 2008) 
highlighted the importance of polymorphisms in the metabolic pathway in 
mediating formation of toxic methylated arsenical metabolites. 
The use of biomarkers beyond the individual level has not always allowed for 
cause-effect relationships. A major limitation of biomarker use is that a variety of 
responses have been identified in exposed organisms, making difficult to link 
environmental exposure to specific chemical entities and subsequent biological 
effects. Variability in biomarker responses may be attributed to abiotic 
(temperature, salinity, dissolved oxygen, etc.) or biotic factors (genotype, 
phenotypic plasticity, tolerance, age, sex, body size, etc.). In this case, the use of a 
multi-biomarker approach, in a range of species using sentinel organisms, becomes 
necessary to resolve or at least have a closer insight into complex environmental 
problems (Mussali-Galante et al., 2013). 
 
 
1.4 Matrix metalloproteinases   
Matrix metalloproteinases (MMPs) are a family of at least 23 endopeptidases that 
act as effectors of extracellular matrix remodeling in physiological and pathological 
conditions (Figure 1.3). All family members are secreted as inactive proenzymes 
(zymogens) and are thought to be activated in the tissue by cleavage of the 
propeptide. All MMPs contain Zn
2+
 at the catalytic site and, in addition, require 
Ca
2+
 for stability and activity (Birkedal-Hansen, 1993). MMPs can be subdivided 
into gelatinases (MMP-2 and -9), collagenases (MMP-1, -8, -13 and -18), 
stromelysins (MMP-3, -10 and -11) and other MMPs, according to their substrate 
affinity profile. Their activity is closely regulated by tissue inhibitors of 
metalloproteinases (TIMPs), a group of four endogenous antagonists that bind to 
the catalytic site of MMPs. MMPs participate in normal remodeling processes such 
as embryonic development, post-partum involution of the uterus, bone remodeling, 










endopeptidases able to degrade extracellular matrix proteins in a variety of physiological and 
pathological processes. 
 
MMPs hydrolyze extracellular matrix components in a variety of processes ranging 
from implantation and embryogenesis to inflammation, metastasis, and 
angiogenesis (Hernandez-Perez and Mahalingam, 2012). Metalloproteinases, whose 
production is enhanced by prostaglandins, play an important role in promoting 
uterine contractions and preterm birth by stimulating cervical ripening and 
membrane activation (Xu et al., 2002). In particular, metalloproteinases degrade 
extracellular matrix proteins, such as collagens and fibronectins, leading to 
weakening of membranes and their subsequent rupture (Vu et al., 2008). In a recent 
study by Sundrani et al. (2012), placental metalloprotein 1 and metalloprotein 9 
levels were significantly increased in women with spontaneous preterm birth 
compared to those delivering at term, suggesting that placental metalloprotein 
1/metalloprotein 9 levels may be involved in the initiation of parturition (Maymon 
et al., 2000). Polymorphisms in metalloproteinases and TIMPs have been found to 
modulate the risks for preterm premature rupture of membranes (PPROM) and 
preterm birth (Maymon et al., 2000; Cockle et al., 2007).  
MMPs are also thought to modulate the effects of heavy metals especially Hg. 
Several polymorphisms in metalloproteinases and TIMPs have been found to 
modulate the effects of heavy metal exposure (especially Hg) on the risk of 
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cardiovascular diseases (Pepper, 2001). Indeed, MMP-2 and -9 have emerged as 
important players in a number of cardiovascular diseases, including atherosclerosis, 
stroke, heart failure, ischemic heart disease and aneurysm (Kupai et al., 2010). 
Also, the single nucleotide polymorphisms in these genes are associated with 
differential risk of preterm birth (Jacob-Ferreira et al., 2011; Jacob-Ferreira et al., 
2010). Several other oxidative stress-related genes have been associated 
independently with heavy metals exposure and adverse pregnancy outcomes. It may 
be suggested that the effect of Hg on glial cell reactivity and Hg-induced oxidative 
stress via MMPs or paraoxonase 1 (PON1) modulating the effects of heavy metals 
seem also to play a role in the pathogenesis of preterm birth, perinatal hypoxia, 
bronchopulmonary dysplasia (BPD), preterm brain inflammation, and mortality 
(Türker, 2015). 
Air pollutants, including heavy metals (e.g. Cd, Pb and Hg), can reach the 
respiratory system, eliciting pulmonary and/or systemic effects, which include 
inflammation, tissue remodeling and carcinogenesis: all phenomena where MMPs 
play critical roles, given their broad effects on matrix remodeling and modulation 
of inflammation and cell signaling (Löffek et al., 2011). In an in vitro study, Xu et 
al. (2011) evaluated modulation of MMP-2 and -9 expression by Ni on human lung 
cancer cell lines A549 and H1299 in the context of the analysis of their growing 
capacity and invasiveness. They demonstrated that Ni could significantly enhance 
the invasive potential of A549 and H1299 cells in a dose-dependent manner. This 
was accompanied by an elevated expression of interleukin (IL)-8, transforming 
growth factor-β and MMP-2 and MMP-9 proteins (Dagouassat et al., 2012). 
Fievez et al. (2009) examined MMP-2 and -9/TIMP-1 and -2 imbalance in rats 
exposed to Cd nebulisation. Such nebulisation induced a significant increase in 
bronchoalveolar lavage (BAL) MMP-2 and -9 and TIMP-2 expression and/or 
activities. In a descriptive in vivo study, Beaver et al. (2009) showed an increase in 
the levels of pro-MMP-9 in BAL fluid, strongly correlating with the presence of 
neutrophils in the airways, in mice exposed chronically to particles of hexavalent 
chromium (Cr(VI)), a well-known pro-inflammatory and carcinogenic agent 
(Fishbein, 1981). Wan et al. (2008) demonstrated that nanoparticles of Co, but not 
nanoparticles of titanium dioxide (TiO2), induced MMP-2 and -9 activity and 
mRNA expression, and decreased mRNA expression of TIMP-2. 
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It has been demonstrated that divalent metal salts, as Zn, Cu, Hg and Sn, are 
capable to inhibit the activity of MMP-2 and MMP-9 at low concentration (Souza 
et al., 2000). It has also been observed that Pb, Cd and Zn inhibit the activity of 
enamel MMPs in vitro (Gerlach et al., 2000; Souza and Line, 2002). 
Study of the pattern of MMP expression in response to heavy metals could provide 
important insights into the pathogenesis of clinical syndromes associated with toxic 
metal exposure. Furthermore, studies of metalloproteinase expression in response to 
heavy metals may provide a general model for tissue injury applicable to a wide 
range of lesions (Evans, 2015). 
 
 
1.5 Aim of the project 
This research project has aimed to study the proteome of tissues of malformed 
fetuses exposed to heavy metals. This project is based on the proteomic analysis of 
umbilical cords (Figure 1.4) of malformed fetuses, obtained by therapeutic 
abortions, using as control umbilical cords of healthy fetuses with similar 
gestational age (psychiatric abortions). All umbilical cords have come from Caserta 
Hospital “Sant’Anna e San Sebastiano” and from Avellino Hospital “San Giuseppe 
Moscati”, which collect cases from the whole territory of the Campania Region; the 
umbilical cords were obtained by therapeutic abortions of mothers resident for 
more than 10 years in the areas of the provinces of Naples and Caserta, unhappily 
known as the “land of fires”. The comparison between the protein profiles observed 
in the umbilical cords of malformed fetuses and those of healthy fetuses with 
comparable gestational age may allow to individuate new possible specific 
biomarkers of exposure. Main aims: 
 identification of down or upregulated proteins; 
 study of proteomic data by complementary techniques; 






Figure 1.4. Umbilical cord. Aim of this project was to study the proteome of umbilical cords. Cord 
tissue contains several different cell types, including mesenchymal stem cells, epithelial cells and 
























2 Materials and Methods 
2.1 Umbilical cords from healthy and malformed fetuses 
Caserta Hospital “Sant’Anna e San Sebastiano” and Avellino Hospital “San 
Giuseppe Moscati” (consent of the Ethics Committee, January 2014): 
2014: GR1 (Healthy); GR2 (Healthy); GR3 (Healthy); GR4 (Healthy); GR5 
(Healthy); GR6 (Healthy); GR7 (Healthy); GR8 (Healthy); GR9 (Healthy); GR10
 (Healthy); CCP PSI 1 (Healthy); CC10 (Trisomy 21); G7 (Trisomy 21); CC31
 (Diaphragmatic hernia); CC32 (Non-immune hydrops); CC33 (Cystic hygroma and 
atrioventricular canal defect); CC35 (Congenital heart disease); G6 (Trisomy 21); 
G9 (49,XXXXY syndrome). 
2015: CCP PSI 2 (Healthy); CC3C(15) (Healthy); CCP PSI 3 (Healthy); CC(15)D 
(Healthy); G16 (47,XXY, Klinefelter syndrome); G5 (Trisomy 21); CC1(15)
 (Neural tube defect – multiple); CC5(15) (Neural tube defect); G1 (Trisomy 21 + 
heart disease); G2 (Dyssegmental dysplasia, Silverman-Handmaker); G3 (Trisomy 
21); G4 (Trisomy 21); G11 (Neural tube defect); CC7(15) (Gastrointestinal 
disease); CC8(15) (47,XXY, Klinefelter syndrome); CC9(15) (Congenital heart 
disease, cleft lip and palate, neural tube defect). 
 
 
2.2 Protein extraction and quantitative analysis 
Preliminary experiments were realized to select the best method of protein 
extraction from umbilical cords, crucial step for the subsequent analyses.  
Umbilical cord proteins were extracted by cryogenic grinding with mortar and 
pestle in dry ice of  frozen tissue (100 mg) and by suspending in 600 µl of lysis 
buffer (7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 40 mM DTT, 0.5% ampholytes) 
added with protease inhibitor (1:100 v/v). The mixture was vortexed, centrifuged at 
13,000 g for 15 min and the supernatant was collected. The protein concentration of 
each extract was determined according to the Bradford method (Bradford, 1976), 
which is a colorimetric assay based on an absorbance shift of the dye Coomassie 
Brilliant Blue G-250. It was constructed a calibration curve with bovine serum 
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albumin (BSA) (1 µg/µl, 2.5 µg/µl, 5 µg/µl, 10 µg/µl, 20 µg/µl). 1 µl of lysate was 
added to 1 ml of the mixture H2O:Bradford reagent (8:2 v/v) and the assay 
 was performed by UV-visible spectrophotometer at 595 nm. 
 
 
2.3 One-dimensional gel electrophoresis and in gel digestion 
In a first step umbilical cords were analyzed by one-dimensional Sodium Dodecyl 
Sulfate - PolyAcrylamide Gel Electrophoresis (SDS-PAGE) approach, followed by 
‘in gel’ enzymatic digestion with trypsin (Wilm et al., 1996). Briefly, each protein 
extract (70 µg) was dissolved in SDS-PAGE loading buffer (4% SDS, 20% 
glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol blue, 0.125 M Tris-HCl, 
pH 6.8), boiled at 100°C for 5 min, and loaded in triplicate on a 1.5-mm thick 10% 
polyacrylamide gel. 5 µl of protein standard marker (Protein Marker VI (10 – 245) 
prestained, AppliChem, Darmstadt, Germany) were loaded alongside of each gel. 
The protein separation was performed at constant 30 mA/gel for 2 h at room 
temperature. Gels were stained by colloidal Coomassie Brilliant Blue staining 
solution and scanned by ImageScanner III LabScan 6.0 software (GE Healthcare). 
Resulting electrophoretic lanes were cut in 10 slices. The gel slices were washed 
and destained 3 times in deionized water, cysteines were reduced with 10 mM DTT 
in 100 mM ammonium bicarbonate buffer for 1 h at 56°C and then alkylated with 
50 mM iodoacetamide in 100 mM ammonium bicarbonate buffer for 30 min at 
room temperature in the dark. Digestion was performed overnight at 37°C with 13 
ng/μl trypsin (Promega, Madison, WI, USA) in 25 mM ammonium bicarbonate 
buffer. The resulting peptides were extracted with 0.1% formic acid in acetonitrile, 
dried in a vacuum centrifuge, and resuspended in 30 μl 0.1% formic acid in water 
for mass spectrometric analysis. 
 
 
2.3.1 Mass spectrometry-based protein identification 
Protein identification was performed by reverse-phase high-performance liquid 
chromatography (RP-HPLC) coupled to electrospray ionization tandem mass 
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spectrometry (ESI-MS/MS). Peptide mixtures produced by tryptic digestion (5 μl) 
were sequentially loaded on a reversed-phase column (0.1×150 mm, packed with 
C18, 5 μm, 100 Å) at a flow rate of 60 μl/min with buffer A (0.1% formic acid in 
water). The samples were run on a 73-min gradient, which consisted of a 5%–45% 
buffer B (0.1% formic acid in acetonitrile/water 80/20) for 55 min, 90% buffer B 
for 5 min, and 5% buffer B for 13 min. The peptide analysis was performed using 
the LTQ ORBitrap XL (Thermo Fisher Scientific) coupled directly to the LC 
column via a nano-electrospray source. The MS survey scan was obtained for the 
m/z range 400–1800, and the MS/MS spectra were acquired from the survey scan 
for the 10 most intense ions as determined by the Xcalibur mass spectrometer 
software in real time. Dynamic mass exclusion windows of 60 s were used to limit 
repeated sequencing (Song et al., 2009). 
The thirty raw data MS/MS spectra from the three electrophoretic lanes of each 
sample were converted in MGF format by MM File Conversion tool for subsequent 
protein identification against the Swiss-Prot Protein Database (542,782 sequence 
entries, March 2014) through the MS search algorithm on the Mascot search engine 
(Perkins et al., 1999). The following search parameters were set: Peptide tolerance 
25 ppm; MS/MS tolerance 0.8 Da; enzyme specificity: trypsin; 2 missed cleavages 
permitted; fixed modification: carbamidomethylation of cysteine; variable 
modification: methionine oxidation; taxonomy: Homo sapiens. 
The ten MGF files from each electrophoretic lane were merged into a single search 
in order to output a single list of identified proteins. 
 
 
2.4 Two-dimensional gel electrophoresis (2-DE) 
Protein lysates (500 μg for each sample) were precipitated in acetone for sample 
purification, rehydrated with suitable buffer (7M urea, 2M thiourea, 2% w/v 
CHAPS, 0.5% v/v Pharmalyte pH 3-10, 0,002% v/v Bromophenol blue stock 
solution 1%) with 2,8 mg/ml of dithiothreitol (DTT) and loaded on IPG strips 18 
cm  (pH 3-10 nonlinear). IPG strips were inserted in Ettan IPGphor3 system (GE 
Healthcare) for IEF in first dimension and were subsequently equilibrated with a 
buffer containing SDS (50mM Tris/HCl, 6M urea, 30% glycerol, 2% SDS) before 
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the electrophoresis in second dimension. An aliquot of equilibration buffer was 
added with DTT (100 mg in 10 ml of solution) for reduction of denatured proteins, 
a second aliquot of equilibration buffer was instead added with iodoacetamide 
(IAA) (250 mg in 10 ml of solution) for subsequent alkylation of the reduced 
sulfhydryls. Each IPG strip was then loaded on gel for the separation in second 
dimension. Gels were then fixed in 40% ethanol, 10% acetic acid for 3 h, stained in 
0.1% Coomassie Brilliant Blue R-250 and destained in 30% ethanol, 10% acetic 
acid. After coloration with Coomassie blue, gels were scanned and acquired by 
Image Scanner III LabScan 6.0 software (GE Healthcare). Gel images were 
analyzed using ImageMaster 2D Platinum 6.0 software (GE Healthcare) according 
to manufacturer’s instructions. Image analysis included spot detection, 
quantification and matching. 
 
  
2.5 Filter-Aided Sample Preparation (FASP) 
In the Filter-Aided Sample Preparation (FASP) method, umbilical cord proteins 
were extracted by cryogenic grinding with mortar and pestle in dry ice of frozen 
tissue (100 mg) and by suspending in 600 µl of lysis buffer (4% SDS, 100 mM 
Tris/HCl pH 7.6, 0.5 mM DTT) added with protease inhibitor (1:100 v/v). The 
mixture was vortexed, incubated at 95°C for 3 min, centrifuged at 13,000 g for 5 
min and the supernatant was collected. The protein concentration of each extract 
was determined according to the DC Protein Assay (Bio-Rad), which is a 
colorimetric assay for protein concentration following detergent solubilization 
similar to the well-documented Lowry assay (Lowry et al., 1951; Peterson, 1979). 
The assay was performed in duplicate with a 96-well plate. It was constructed a 
calibration curve with BSA (1 µg/µl, 2.5 µg/µl, 5 µg/µl, 10 µg/µl, 20 µg/µl). 20 μl 
of reagent S (surfactant solution) were added to 1 ml of reagent A (reagent A'). 5 µl 
of lysate were loaded into each well. 25 μl of reagent A' and then 200 μl of reagent 
B were added into each well. After 15 minutes at room temperature in the dark, the 
absorbances were read by UV-visible spectrophotometer at 750 nm.  
The FASP method uses centrifugal filters with a molecular weight cut-off, which 
allow to desalt and concentrate the sample. The filter unit then acts as a ‘proteomic 
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reactor’ for detergent removal, buffer exchange, chemical modification and protein 
digestion. The four critical steps of the FASP method are: (i) depletion of 
detrimental low-molecular-weight components in urea-containing buffer, (ii) 
carboamidomethylation of thiols, (iii) digestion of proteins and (iv) elution of 
peptides (Wiśniewski et al., 2009). After some preliminary checks, filters with a 
cut-off of 10 kDa (Microcon® Centrifugal Filters, EMD Millipore
TM
) were used. 50 
μg of protein extract were loaded on each filter. Detergent removal by buffer 
exchange was performed in two successive washes with UA (8M urea in 100 mM 
Tris-HCl pH 8.5) with a 20 min spin at 13,000 g. Proteins were reduced by adding 
100 mM DTT in UA. Proteins were then alkylated with 50 mM IAA in UA at room 
temperature for 30 min in darkness. Urea was then removed by two washes with 50 
mM ammonium bicarbonate with centrifugation at 13,000 g for 15 min. Protein 
digestion was achieved by adding 0.5 μg of trypsin (enzyme to protein ratio 1:100) 
in 50 mM ammonium bicarbonate to each filter and incubating at 37°C overnight. 
Peptides were recovered in two washes with 40 μl of 50 mM ammonium 
bicarbonate with spinning at 13,000 g for 20 min each. Peptides resulting from 
digestion were desalted by StageTips (C18 material 200μL, Thermo Scientific
TM
) 
according to manufacturer’s instructions and analyzed by LC/MS/MS (LTQ-





2.5.1 Mass spectrometry-based protein identification 
Peptides were separated on a EASY-nLC 1000 HPLC system (Thermo Fisher 
Scientific). Columns (75-μm inner diameter, 25-cm length) were in-house packed 
with 1.9-μm C18 particles. Peptides were loaded in buffer A (0.1% formic acid) 
and separated with a gradient from 7% to 60% buffer B (80% acetonitrile, 0.1% 
formic acid) within 3.5 h at 200 nl/min. A quadrupole Orbitrap mass spectrometer 
(Thermo Fisher Scientific) was directly coupled to the liquid chromatograph via a 
nano-electrospray source. The survey scan range was set to 400 to 1,800 m/z. Up to 
the 10 most abundant isotope patterns with a charge of ≥2 were subjected to 
Higher-energy collisional dissociation with a normalized collision energy of 25, an 
isolation window of 2 Th, and a resolution of 17,500 at m/z 200. To limit repeated 
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sequencing, dynamic exclusion of sequenced peptides was set to 60 s. Thresholds 
for ion injection time and ion target value were set to 20 ms and 3 × 10
6
 for the 
survey scans and to 60 ms and 10
6 
for the MS/MS scans (Hornburg et al., 2014). 
Data were acquired using Xcalibur software (Thermo Fisher Scientific). 
LC/MS/MS analysis was performed in duplicate. 
The protein identification and quantification was performed by MaxQuant 1.5.2.8 
software (Max Planck Institute of Biochemistry). In MaxQuant all MS files were 
uploaded simultaneously, specifying the experiment name in order to get a different 
MaxLFQ (Label-Free Quantification) intensity for each MS run. The MS/MS 
spectra were searched against the UniProtKB HUMAN fasta database (70,071 
forward entries; version of October 2015). MaxQuant validates scoring statistics 
based on hits to reversed protein entries in a target-decoy database. Therefore, it 
was necessary to include a reversed version for each original entry in the protein 
database fasta file. Reversed entries have to be indicated by a recognizable prefix to 
the protein ID, e.g. ‘REV_’ (Cox et al., 2009). Enzyme specificity was set to 
trypsin allowing cleavage N-terminal to proline and up to 2 miss cleavages. 
Peptides had to have a minimum length of 5 amino acids to be considered for 
identification. Carbamidomethylation was set as fixed modification, acetylation (N-
terminus) and methionine oxidation were set as variable modifications. A false 
discovery rate (FDR) cutoff of 5% was applied at the peptide and protein level. 
Initial precursor mass deviation of up to 4.5 ppm and fragment mass deviation up to 
20 ppm were allowed. Protein identification required a minimum peptide ratio 
count of 1 and at least one razor peptide. Razor peptides are non-unique peptides 
assigned to the protein group with the most other peptides (Occam’s razor 
principle) (Cox et al., 2009). Proteins that could not be discriminated on the basis 
of unique peptides were grouped into protein groups. MaxLFQ intensities were 
used to quantify fold changes of proteins across samples,  (Hornburg et al., 2014). 
 
 
2.5.2 Gene Ontology 
Gene Ontology was performed using the PANTHER 
(Protein Analysis THrough Evolutionary Relationships) Classification System 
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(http://www.pantherdb.org/), which is part of the Gene Ontology Reference 
Genome Project. The PANTHER matches gene function, ontology, pathways and 
statistical analysis, and allows to analyze data of large-scale complete genomes 
coming from experiments of sequencing, proteomics or gene expression. Proteins 
and their genes are classified according to: family and subfamily; molecular 
function; biological process; pathway (Mi et al., 2013). 
 
 
2.6 Gelatin zymography 
Zymography is known as an electrophoretic technique, commonly based on SDS-
PAGE, suitable for analysis of matrix metalloproteinases (MMPs) in complex 
biological fluids (serum, synovial fluid) and tissue extracts (heart, liver, kidney, 
spleen, etc.). 
Samples (50 mg) were prepared in a standard, non-reducing loading buffer (62.5 
mM Tris-HCl pH 6.8, 2.5% SDS, 0.002% Bromophenol Blue, 10% glycerol) 
for the separation by SDS-PAGE. No reducing agent (2-mercaptoetanol, DTT) or 
boiling are necessary since these would interfere with refolding of the enzyme. A 
suitable substrate (e.g. gelatin for protease detection) was embedded in the 
resolving gel during preparation of the acrylamide gel (10% polyacrylamide–0.1% 
gelatin). Protein concentration was determined by DC Protein Assay (Bio-Rad, 
Berkeley, CA, USA), using BSA as a standard. 150 µg of proteins, of each sample, 
were loaded on the gel. Following electrophoresis, the SDS was removed from the 
gel (or zymogram) by incubation in unbuffered Triton X-100 2,5%, followed by 
incubation in an appropriate digestion buffer (40mM Tris pH 7.5, 0.2M NaCl, 
10mM CaCl2) for an optimized length of time (~16 h) at 37 °C. Gels were stained 
with Coomassie blue and were then destained. Gelatinolytic activity was visualized 
as clear bands against a blue background. The intensity of each band present was 
performed with ImageJ software (http://rsbweb.nih.gov/ij/download.html). The 






2.7 Western blotting analysis 
Umbilical cord whole lysates for immunoblot analysis were prepared according to 
the standard protocol. Protein concentration was determined by DC Protein Assay 
(Bio-Rad, Berkeley, CA, USA), using bovine serum albumin (BSA) as a standard. 
Proteins were fractionated on SDS-PAGE, transferred into nitrocellulose 
membranes, and immunoblotted with appropriate primary antibodies. Signals were 
visualized with appropriate horseradish peroxidase-conjugated secondary 
antibodies and enhanced chemiluminescence (Amersham Biosciences-GE 




2.8 Statistical analysis 
Data reported in each figure are the mean values ± SD from at least three 
experiments, performed in duplicate, showing similar results. Differences between 
treatment groups were analyzed by Student’s t-test. Differences were considered 


















3 Results and Discussion 
The aim of this project was to study the proteome of umbilical cords from 
malformed fetuses compared to healthy ones with same gestational age. All 
umbilical cords were obtained by therapeutic abortions of women living in Napoli 
or Caserta, in the so-called “land of fires” (Figure 3.1). The collection of the 
biological samples was carried out in collaboration with the Caserta Hospital 
“Sant’Anna e San Sebastiano” and with the Avellino Hospital “San Giuseppe 
Moscati” (The hospital ethics committee has reviewed and approved the project). 
The comparison between the protein profiles observed in umbilical cords of 
malformed and healthy fetuses may allow to identify differentially expressed 
proteins. The down or up-regulated proteins may indicate the biological pathways 
involved in the contaminants toxicity (González-Fernández et al., 2008). Gene 
Ontology (GO) classification was used in order to obtain functional information of 
the differentially expressed proteins, and to correlate them to the embryonic 
development. Matrix Metalloproteinases (MMPs) have been shown to play 
significant roles in a number of physiological processes, including embryogenesis 
and angiogenesis,  they also contribute to the development of pathological 
processes. Thus, gelatin zymography technique was set up and performed for 
detection of MMPs enzymatic activity in the umbilical cords. At delivery,  mothers 
consented for umbilical cords of fetus and for their  hair sample be taken. By the 
administration of a questionnaire (Appendix A) were obtained data of  historical 
residence of the parents of the malformed fetuses (last 10 years), genetic 
background, reproductive history, exposures to environmental risks, to use of 
chemicals.  This was important in order to analyze two important aspects in the 
study of the malformation: the possible genetic background of  the family  and 
potential risks arising from the work environment. Data of historical exposure (time 
of living in a place) are very important to establish correlations between a possible 
environmental effect and a phenotype (fetal malformation). The metal 
contamination was measured by Prof. Stefania Papa, Seconda Università  di Napoli, 
and by analyzing the concentrations of the metals in mother hair during the first 
trimester of pregnancy. The analysis of mother hair for about 25 carcinogenic, 
teratogenic and toxic metals was performed by atomic spectrometry, the method 
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recommended by the International Atomic Energy Agency (IAEA) to verify the 
individual exposure to metal contamination present in the environment (Bass et al., 
2001). Quali-quantitative measures of the same metals were also performed on 





Figure 3.1. “Land of fires”. The umbilical cords were collected by therapeutic abortions of mothers 
living for more than 10 years  in the towns of Acerra, Casal di Principe, Casalnuovo di Napoli and 
Santa Maria Capua Vetere.     
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3.1 Umbilical cords from healthy fetuses 
In order to set up the experimental protocols, umbilical cords from healthy fetuses 
were collected by Dr. G. Rivezzi of the Caserta Hospital “Sant’Anna e San 
Sebastiano” (Table 3.1). The samples were transported in dry ice, dissected into 
aliquots of about 100 mg, washed with cold phosphate-buffered saline (PBS: 10 
mM NaH2PO4; 2.7 mM KCl; 137 mM NaCl; pH 7.4) to remove contaminating 
blood and stored at -80°C. 






GR1 Healthy 36 2014 
GR2 Healthy 36 2014 
GR3 Healthy 34 2014 
GR4 Healthy 32 2014 
GR5 Healthy 36 2014 
GR6 Healthy 36 2014 
GR7 Healthy 38 2014 
GR8 Healthy 39 2014 
GR9 Healthy 36 2014 
GR10 Healthy 36 2014 
 
 
3.2 Protein extraction and quantitative analysis 
Umbilical cord proteins were extracted as previously described (see “materials and 
methods”). The protein concentration of each extract was determined according to 
the Bradford method (Bradford, 1976). The protein concentrations measured for the 




















3.3 One-dimensional SDS-PAGE and in-gel digestion 
In a first step the umbilical cords were analyzed by one-dimensional SDS-PAGE 
approach, followed by ‘in gel’ enzymatic digestion with trypsin. Each protein 
extract (70 µg) was dissolved in SDS-PAGE loading buffer and loaded in triplicate 









Figure 3.2. One-dimensional SDS-PAGE of protein extracts of umbilical cords from healthy 
fetuses: A) GR1; B) GR2; C) GR3; D) GR4, GR5, GR6; E) GR7; F) GR8. Each sample was 




Resulting electrophoretic lanes were cut in 10 slices, that underwent in-gel tryptic 
digestion. Peptides were extracted, dried in a vacuum centrifuge, and resuspended 
for mass spectrometry-based analysis. 
 
3.3.1 Mass spectrometry-based protein identification 
The peptides resulting from the digestion were analyzed by nanoLC/MS/MS.  
The protein identification was performed by Mascot search engine against the 
Swiss-Prot Protein Database. Mascot search engine assigns at each protein the 
parameter emPAI (exponentially modified Protein Abundance Index) for the 
absolute quantization of the protein in complex protein mixtures (Ishihama et al., 
2005).  
























emPAI Protein names 
28 21542 6 1 5 1 0,18 1,2dihydroxy3-keto-5-methylthiopentene dioxygenase 
46 80879 12 1 12 1 0,05 1,4-alpha-glucan-branching enzyme 
210 28179 32 8 16 7 1,74 14-3-3 protein beta/alpha 
252 29326 36 9 15 6 1,07 14-3-3 protein epsilon 
132 28372 29 4 16 4 0,65 14-3-3 protein eta 
207 28456 29 6 11 3 0,87 14-3-3 protein gamma 
62 27871 21 3 11 3 0,47 14-3-3 protein sigma 
215 28032 25 6 11 2 0,66 14-3-3 protein theta 
551 27899 39 17 18 9 4,25 14-3-3 protein zeta/delta 
25 32038 34 1 8 1 0,12 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha 
20 42387 11 2 10 1 0,09 1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon 
28 122861 16 1 14 1 0,03 2'-5'-oligoadenylate synthase 3 
47 37060 6 1 6 1 0,1 26S proteasome non-ATPase regulatory subunit 7 
51 39872 14 1 13 1 0,09 26S proteasome non-ATPase regulatory subunit 8 
30 27134 11 1 9 1 0,14 3-hydroxyacyl-CoA dehydrogenase type-2 










emPAI Protein names 
49 80879 12 2 10 2 0,09 1,4-alpha-glucan-branching enzyme 
346 28179 38 7 16 3 0,46 14-3-3 protein beta/alpha 
370 29326 51 11 17 5 0,84 14-3-3 protein epsilon 
339 28456 38 8 15 3 0,65 14-3-3 protein gamma 
399 28032 26 8 9 3 0,66 14-3-3 protein theta 
644 27899 42 15 13 6 1,78 14-3-3 protein zeta/delta 
44 32038 49 4 8 1 0,12 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha 
18 30074 48 1 8 1 0,13 2-aminoethanethiol dioxygenase 
23 26842 21 1 13 1 0,14 40S ribosomal protein S3 
26 32947 14 1 12 1 0,11 40S ribosomal protein SA 
15 122531 43 1 29 1 0,03 5-azacytidine-induced protein 1 
39 61187 21 2 14 2 0,13 60 kDa heat shock protein, mitochondrial 
34 61372 32 2 14 2 0,12 60 kDa SS-A/Ro ribonucleoprotein 
34 11621 5 1 2 1 0,34 60S acidic ribosomal protein P1 
158 86454 48 10 30 10 0,52 6-phosphofructokinase type C 










emPAI Protein names 
128 28179 30 3 18 2 0,46 14-3-3 protein beta/alpha 
88 29326 21 2 14 2 0,28 14-3-3 protein epsilon 
56 28372 22 1 14 1 0,13 14-3-3 protein eta 
196 28456 27 6 12 3 0,65 14-3-3 protein gamma 
29 27871 20 1 12 1 0,14 14-3-3 protein sigma 
61 28032 18 1 12 1 0,13 14-3-3 protein theta 
468 27899 36 11 23 7 2,15 14-3-3 protein zeta/delta 
38 32038 33 6 4 1 0,12 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha 
21 53270 19 1 14 1 0,07 26S proteasome non-ATPase regulatory subunit 12 
17 12621 15 1 4 1 0,31 28S ribosomal protein S33, mitochondrial 
21 27134 10 1 8 1 0,14 3-hydroxyacyl-CoA dehydrogenase type-2 
28 18886 4 1 4 1 0,2 40S ribosomal protein S10 
40 13791 6 1 4 1 0,29 40S ribosomal protein S25 
32 23033 8 1 4 1 0,17 40S ribosomal protein S5 
63 11621 5 2 3 1 0,34 60S acidic ribosomal protein P1 










3.3.2 Assessment of technical variability 
The three lists were aligned manually on the basis of the quantitative mascot 
parameter (emPAI) in order to calculate mean and standard deviation for the 
measured amount of each protein. Each protein may be present in only one, two or 
all three lists. Where a protein wasn’t detected, a zero emPAI value was added.  
Finally a single list of proteins (~ 1000 identified proteins) was obtained for each 
sample, where a mean emPAI value and the relative standard deviation was 
reported for each protein (Table 3.4). 
It wasn’t possible to calculate mean and standard deviation for the samples GR1 
and GR2, because their three lists were very different as number of identified 
proteins. Therefore, the samples GR1 and GR2 were discarded.  
Table 3.4. Mean and standard deviation of proteins for each sample. 
Protein names Mean 
Standard 
deviation 
14-3-3 protein beta/alpha 1,10 0,91 
14-3-3 protein epsilon 0,68 0,56 
14-3-3 protein eta 0,39 0,37 
14-3-3 protein gamma 0,76 0,16 
14-3-3 protein sigma 0,31 0,23 
14-3-3 protein theta 0,40 0,37 
14-3-3 protein zeta/delta 3,20 1,48 
1-acyl-sn-glycerol-3-phosphate acyltransferase alpha 0,12 0,00 
3-hydroxyacyl-CoA dehydrogenase type-2 0,14 0,00 
40S ribosomal protein S10 0,20 0,00 
60S acidic ribosomal protein P1 0,34 0,00 
6-phosphofructokinase type C 0,29 0,16 
Actin, aortic smooth muscle 46,50 8,49 
Actin, cytoplasmic 1 13,83 2,67 
Actin-related protein 2 0,08 0,00 
Actin-related protein 2/3 complex subunit 4 0,19 0,00 
Adapter molecule crk 0,11 0,00 
Adenosylhomocysteinase 0,12 0,06 
Adenylate kinase isoenzyme 1 0,63 0,00 
Adenylyl cyclase-associated protein 1 0,28 0,06 
Adenylyl cyclase-associated protein 2 0,07 0,00 
Adipocyte enhancer-binding protein 1 0,06 0,04 
ADP-ribosylation factor 1 0,82 0,22 
Afamin 0,05 0,00 
Aldehyde dehydrogenase X, mitochondrial 0,17 0,06 
Alpha-1-antichymotrypsin 0,26 0,13 
Alpha-1-antitrypsin 3,14 0,23 





Subsequently, the intra-sample variability was calculated with the following mode 
(Auger et al., 2000): 
Intra-sample variability = 
Mean of the standard deviations
Mean of the means
 × 100 
The intra-sample variabilities were reported in the Table 3.5. 
Table 3.5. Intra-sample variabilities. 








In order to minimize these variabilities, the proteins present in only one of the three 
lists were omitted, while the proteins present in at least two lists on three were 
considered. The intra-sample variabilities thus were recalculated and reported in 
Table 3.6.  
Unfortunately, they were still too high and actually not satisfactory. 
Table 3.6. Intra-sample variabilities recalculated. 
Sample Intra-sample variability 
GR3  65,35% 
GR4  21,86% 
GR5  29,71% 
GR6  63,71% 
GR7  100,22% 






3.4 Two-dimensional gel electrophoresis (2-DE) and image analysis 
In order to overcome the high technical variabilities showed by one-dimensional 
SDS-PAGE analysis, it was then set up a proteomic approach based on two-
dimensional gel electrophoresis (2-DE). All 2-DE experiments were performed on 
test samples of umbilical cords from healthy term fetuses. The umbilical cord 
proteins were separated by IEF using 18 cm IPG strips (pH 3-10NL; GE 
Healthcare) on the basis of their charge (separation in first dimension) and by SDS-
PAGE on the basis of their molecular weight (separation in second dimension). The 
result is an array of protein spots, characterized by precise coordinates x and y: 
isoelectric point (pI) and apparent molecular weight (Mw), respectively. Each spot 
potentially corresponds to a single protein in the sample (Figure 3.3). The gel image 
analysis was performed by ImageMaster 2D Platinum 6.0 software (GE Healthcare) 
according to manufacturer’s instructions; the most significant spots, were subjected 
to ‘in gel’ enzymatic digestion and LC/MS/MS analysis for protein identification. 
The image analysis included spot detection, gel-to-gel matching and spot 
quantification (Raman et al., 2002). Manual editing (e.g. deletion of false protein 
spots and correction of spot shape) during the spot detection is nearly impossible to 
avoid due to complexity of spots on a gel as well as manual matching because of 
dissimilarity of spot positions. However, an excessive manual interventions should 
be avoided to increase the reliability of the image control and the reproducibility of 
the procedure (Magdeldin et al., 2014). Ambiguous regions, such as crowded areas 
or areas containing high-molecular-weight proteins that were not well defined, were 
discarded. Some of the spots detected at the boundaries of the gels and not 
satisfactorily resolved were also excluded from further analysis. Therefore, the 
number of the spots detected was always below that expected from the resolution 
capability of the technique; this result is related to our choose to use a conservative 
approach for the analysis of the gels, counting only clearly defined spots and not 




























Figure 3.3. 2-DE of protein extracts of umbilical cords from healthy fetuses: A) GR1; B) GR2; C) 







3.4.1 Limitations of 2-DE 
Several limitations intrinsically related to the use of a 2-DE electrophoresis-based 
approach emerged. Firstly, this project involved the screening of a large number of 
clinical samples; since 2-DE is labor-intensive and has a relative low throughput, 
that represented a serious obstacle for a project like this. 
Secondarily, there could also be a progressive loss of basic proteins during long 
running of electro-focusing under electric field, leading to low reproducibility and 
requiring careful monitoring of electric field (Magdeldin et al., 2012). 
Different types of proteins can always be missing, due to the difficulty in separating 
membrane-bound (hydrophobic) and extreme proteins (highly acidic or basic) 
(Wilkins et al., 1998). 
Low dynamic range of proteins is one of the challenging problems encountered 
during 2-DE. Low-abundance proteins are rarely seen on traditional 2D maps 
because large quantities of abundant soluble proteins obscure their detection. 
Moreover, the visualization of faint protein spots (low abundant) separated on 2-DE 
gels is also governed by staining sensitivity (Chevalier, 2010). 
Spot detection software sometimes lead to missing some data because of the 
mismatching error resulted due to shifted spots between gels or spots overlapping. 
Furthermore, false positive spots are commonly detected due to staining artifacts. 
The relationship between the original protein quantity in the sample and the 
measured spot intensity is affected by various intervening factors (e.g., sample loss 
occurring during the IEF or while transferring to the second dimension) (Magdeldin 
et al., 2014).  
Finally, the umbilical cord is a heterogeneous tissue containing several different 
cell types, including mesenchymal stem cells, epithelial cells and endothelial cells. 
Several umbilical cords had also a significant contamination by blood that 
represented a serious obstacle for the success of the technique. 
Therefore, all these reasons led us to introduce a different gel-free proteomic 






3.5 Umbilical cords from malformed fetuses 
The umbilical cords obtained by therapeutic abortions were collected in 
collaboration with Dr. G. Rivezzi of the Caserta Hospital “Sant’Anna e San 
Sebastiano” and with Dr. C. Ciccone of the Avellino Hospital “San Giuseppe 
Moscati” (consent of the Ethics Committee, January 2014). Twentyfive umbilical 
cords obtained by therapeutic abortions were collected; 20 samples were from 
fetuses affected by different malformations and 5 were control samples from 
healthy fetuses (psychiatric abortions) with similar gestational age (Table 3.7). The 
umbilical cords collected at the Caserta Hospital were indicated with the letter G, 
while the umbilical cords collected at the Avellino Hospital were indicated with the 
letters CC. 
Table 3.7. Umbilical cords obtained by therapeutic abortions. 
 DIAGNOSIS (WEEKS OF GESTATION ~19-21) DATE 
CONTROLS 
CCP PSI 1 Healthy 2014 
CCP PSI 2 Healthy 2015 
CC3C(15) Healthy 2015 
CCP PSI 3 Healthy 2015 
CC(15)D Healthy 2015 
PATHOLOGICALS 
CC10 Trisomy 21 2014 
G7 Trisomy 21 2014 
CC31 Diaphragmatic hernia 2014 
CC32 Non-immune hydrops 2014 
CC33 Cystic hygroma and atrioventricular canal defect 2014 
CC35 Congenital heart disease 2014 
G6 Trisomy 21 2014 
G9 49,XXXXY syndrome 2014 
G16 47,XXY (Klinefelter syndrome) 2015 
G5 Trisomy 21 2015 
CC1(15) Neural tube defect – multiple 2015 
CC5(15) Neural tube defect 2015 
G1 Trisomy 21 + heart disease 2015 
G2 Dyssegmental dysplasia, Silverman-Handmaker 2015 
G3 Trisomy 21 2015 
G4 Trisomy 21 2015 
G11 Neural tube defect 2015 
CC7(15) Gastrointestinal disease 2015 
CC8(15) 47,XXY (Klinefelter syndrome) 2015 
CC9(15) Congenital heart disease, cleft lip and palate, neural tube defect 2015 
 
The samples were transported in dry ice, dissected into aliquots of about 100 mg, 
washed with cold PBS to remove contaminating blood and stored at -80°C for 
further analysis. 
There were several problems for the collection of umbilical cords, such as: 
 authorization by the Ethics Committee of the Caserta Hospital; 
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 consent denied by some mothers; 
 impossibility by some gynecologists to collect and properly treat the material 
collected (-80°C in cryogenic liquid), in particular when the therapeutic 
abortion was performed during the night shift; 
 detachment of the liquid nitrogen dewar at the Avellino Hospital and loss of all 




Figure 3.4. Avellino Hospital “San Giuseppe Moscati”: temperature of the dewar passed from          
-80°C to -20°C for missed production of liquid nitrogen and loss of all samples collected in the end 







3.6 Protein extraction and quantitative analysis 
Umbilical cord proteins were extracted as previously described. The protein 
concentration of each extract was determined according to the DC Protein Assay 
(Bio-Rad), and the protein concentrations measured for the different extracts were 
summarized in the Table 3.8. 





CCP PSI 1 1,78 
CCP PSI 2 1,44 
























3.7 Filter-Aided Sample Preparation (FASP) 
The Filter-Aided Sample Preparation (FASP) method is actually considered a 
crucial technology in the sample preparation for the analysis of complex proteomes. 
It combines the advantages of in-gel and in-solution digestion for mass 
spectrometry–based proteomics. Notably, it combines a strong detergent (SDS) for 
universal solubilization with a chaotropic agent (8 M urea) to efficiently ‘clean up’ 
the proteome before digestion and to obtain purified peptides after digestion, 
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avoiding the disadvantages of the gel format. SDS is the reagent of choice for total 
solubilization of cells and tissues, used as denaturant and as an efficient inactivator 
of proteases (Hernandez-Valladares et al., 2016). Unfortunately, it can preclude 
enzymatic digestion and dominate mass spectra. Therefore, depletion of SDS is a 
prerequisite for efficient mass-spectrometric analysis in proteomics (Wiśniewski et 
al., 2009). The FASP method greatly reduces the time required for sample 
preparation and minimizes sample loss (Manza et al., 2005). It enables more 
flexibility in sample processing, such as successive cleavage, and sample 
fractionation, which increases depth of proteomics analysis and facilitates 
identification of low abundant proteins. An ultrafiltration device was used to retain 
and concentrate the sample, for detergent removal, for depletion of detrimental low-
molecular-weight components, for protein digestion and peptide elution. Proteins in 
the filter unit were alkylated in the urea buffer and were then exchanged into 
ammonium bicarbonate (Ambic) buffer for enzymatic digestion. Advantage of the 
ultrafiltration approach is the purity of the digests, which is a prerequisite for 
effective peptide fractionation and mass spectrometry (Wiśniewski, 2016). Filters 
with relative molecular mass (Mr) cut-offs of 3k and 10k were tested. The number 
of identified peptides with a molecular weight above about 1,5 kDa was much 
reduced for the 3k filter compared to the 10k filter while peptides with masses over 
2,5 kDa were almost completely retained by the 3k filter. As the 10k filter 
efficiently retained small proteins (5–10 kDa) and efficiently released peptides up 
to 5 kDa, it was used as the standard in the subsequent experiments. However, it is 
well known that typically 40–60% of the sample can not be recovered in the filtrate 
because of filter clogging probably produced from poorly digested proteins, large 
peptides, nucleic acids and lipids. Moreover, the sample of interest can be lost in 
case of occasional filter failure (Hernandez-Valladares et al., 2016). All umbilical 
cords obtained by therapeutic abortions were analyzed in duplicate. 50 μg of protein 
extract were loaded on each filter. The method has demonstrated to give excellent 
performance for samples between 25 and 100 μg of total protein. For higher loads, 
a continuous decrease of peptide yield was observed (Wiśniewski, 2016). 0.5 μg of 
trypsin (enzyme to protein ratio 1:100) were added to each filter. Peptides resulting 
from digestion were desalted by StageTips (C18 material 200μL) prior to 





Figure 3.5. Proteomic workflow.  FASP method is followed by StageTip desalting to prepare 
samples for the proteome data set. 
 
 
3.7.1 Mass spectrometry-based protein identification 
The desalted peptides resulting from the digestion were separated and analyzed by 
nanoLC/MS/MS (Figure 3.6). The protein identification and quantification was 
performed by the MaxQuant 1.5.2.8 software. MaxQuant enables high peptide 
identification rates, individualized p.p.b.-range mass accuracies and proteome-wide 
protein quantification (Cox and Mann, 2008). Its algorithm was developed to 
measure a new intensity determination and normalization procedure called 
MaxLFQ, that is fully compatible with any peptide or protein separation prior to 











3.7.2 Statistical analysis 
For the statistical analysis Perseus 1.5.1.6 software was employed, which is part of 
MaxQuant. Since the most of the samples are affected by different malformations, 
they were treated individually and compared with the quadruplicates of all 5 control 
samples pooled as a single big control sample (CTR). So in Perseus the MaxLFQ 
intensities of CTR and the MaxLFQ intensities of a pathological sample in 
quadruplicate were uploaded. Mean and standard deviation were calculated inside 
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the 2 groups. To identify proteins differentially expressed between the 2 groups the 
t-student test was applied, using a p value of 5% for the significances (Roxas and 
Li, 2008). Subsequently a ratio between pathological mean/control mean was 
calculated on the differentially expressed proteins. In the resulting (Table 3.9) table 
the proteins upregulated compared to the control group were indicated in light blue 
and the downregulated ones were in yellow. 




Laminin subunit beta-1 N 
Hemopexin N 
Heat shock protein HSP 90-beta N 
Annexin A6;Annexin N 
GTP-binding nuclear protein Ran N 
Malate dehydrogenase, cytoplasmic;Malate dehydrogenase N 
Fermitin family homolog 1;Fermitin family homolog 2 N 
Angiotensinogen;Angiotensin-1;Angiotensin-2;Angiotensin-3;Angiotensin-4; 
Angiotensin 1-9;Angiotensin 1-7;Angiotensin 1-5;Angiotensin 1-4 
N 
Alpha-1-acid glycoprotein 1 N 
Tropomyosin alpha-1 chain N 
Laminin subunit gamma-1 N 
Nidogen-1 N 
Protein-glutamine gamma-glutamyltransferase 2 N 
Moesin N 
BTB/POZ domain-containing protein KCTD12 N 
Mitogen-activated protein kinase kinase kinase kinase 4 N 
Myb/SANT-like DNA-binding domain-containing protein 4 N 
Peroxiredoxin-6 9,41 
Myosin-9 6,22 
78 kDa glucose-regulated protein 4,67 
Myosin light polypeptide 6 0,00 
Mimecan 0,00 
Keratin, type II cytoskeletal 8 0,00 
N = not divisible by 0, not identified in the control group 
 
All the umbilical cords coming from fetuses affected by trisomy 21 were pooled as 
a single sample (TRIS21) and compared with CTR. 
Fourteen different pairwise comparisons were performed. In order to identify and 
correlate interesting proteins to the embryonic development, common proteins in at 







Table 3.10A. Six of fourteen different pairwise comparisons (pathological samples of 2014).  
Protein names CC31 CC32 CC33 CC35 G9 TRIS21 
Tropomyosin beta chain 2,34 2,71  2,05 2,10 1,60 
Myosin-11 2,70 3,89  3,35 2,73 1,81 
Periostin  1,87 2,71 0,15   
Heat shock protein HSP 90-beta N N  N N N 
Keratin, type II cytoskeletal 8  2,21     
Endoplasmin 3,15 2,99  3,33  6,28 
Annexin A1 2,32 2,30    2,55 
Annexin A2;Annexin;Putative annexin A2 1,58 1,82 0,43   1,52 
Calponin-1 6,95 7,05  5,08 3,55  
Myosin light polypeptide 6 1,86 1,94     
Myosin regulatory light polypeptide 9 3,16 3,70  3,38 3,18 2,13 
Heat shock-related 70 kDa protein 2 N N  N N N 
Collagen alpha-1(XIV) chain 34,70 71,75  22,42 39,79 41,49 
Cysteine and glycine-rich protein 1 8,73 12,83  7,65 5,48 4,53 
Myosin-9 6,49 8,94  8,34 6,01 7,35 
Annexin A6;Annexin  N  N N N 
Histone H1.2 15,05     42,87 
Desmin  2,23     
Filamin-A 2,36 2,44     
Glutathione S-transferase P 11,26 28,52  16,56  14,12 
Collagen alpha-1(XII) chain 5,94 3,12  4,00  2,69 
Tubulin beta chain 5,10 8,14  5,91   
Creatine kinase B-type  N  N N N 
Procollagen C-endopeptidase enhancer 1 N N  N N N 
Mimecan 2,95 2,74    1,89 
Septin-7;Septin-14 N N  N   
Protein disulfide-isomerase A3  7,71   5,76 11,34 
Triosephosphate isomerase  16,08  7,51 7,06 5,33 
Gelsolin  8,13  7,71 8,39 4,59 
Thioredoxin domain-containing protein 5  5,61  5,01  3,58 
78 kDa glucose-regulated protein  4,95    5,96 
Heat shock cognate 71 kDa protein  3,17    2,12 
Protein-glutamine 𝛾-glutamyltransferase 2  N   N  
Cofilin-1   6,26  4,69 4,77 
Keratin, type II cytoskeletal 5 N N  N   
Fibulin-1 4,62 3,66  3,86   
14-3-3 protein zeta/delta 4,15 5,69    4,07 
Collagen alpha-3(VI) chain 4,10 5,29  3,05  2,36 
Neuroblast diff.-associated protein AHNAK 4,10      
Cytoskeleton-associated protein 4 3,34     3,37 
Lumican 2,70 1,88    1,56 
Decorin 2,08 1,79    2,13 
Peroxiredoxin-6  9,03     
Protein S100-A11  N  N N  
Prolargin N N  N N  
L-lactate dehydrogenase B chain  N  N N  
Heat shock 70 kDa protein 1A/1B N N   N  
14-3-3 protein epsilon N  N    
Moesin  N     
Myosin regulatory light chain 12A; 12B N N     
Peptidyl-prolyl cis-trans isomerase A  2,81     
Transgelin-2  N  N  N 
Tropomyosin alpha-3 chain N     N 
Vimentin 1,54      
Calmodulin  5,59     
Pyruvate kinase PKM;Pyruvate kinase  6,00    3,69 
Tubulin beta-4B chain;Tubulin beta-4A chain   3,29    
Pigment epithelium-derived factor    4,90   
Alpha-actinin-4  3,55     
Phosphoglycerate kinase 1  6,01    3,88 
Collagen alpha-1(V) chain  N   N N 
Collagen alpha-1(VI) chain 3,19 3,15    2,67 
Collagen alpha-2(VI) chain 3,49 4,50    2,08 
PDZ and LIM domain protein 7  N  N   
Myosin light chain kinase, smooth muscle  N  N   
Caldesmon     5,35 0,11 
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G2 G11 G16 
Tropomyosin beta chain  2,65  0,00 2,85 0,00 0,00 1,62 
Myosin-11  3,27  0,00 3,53 0,00 0,00  
Periostin 5,35 2,20  0,00 4,95 0,00 0,00  
Heat shock protein HSP 90-beta N N N  N N   
Keratin, type II cytoskeletal 8  2,92 0,00 0,00 2,87 12,64 0,00  
Endoplasmin 6,39 7,28   5,04 3,91   
Annexin A1  2,07  8,58 3,10 2,55 0,00  
Annexin A2;Annexin;Putative annexin A2  2,05   2,23 2,39 0,00  
Calponin-1  3,17   7,01   3,64 
Myosin light polypeptide 6   0,00 0,00 1,63 0,00 0,00  
Myosin regulatory light polypeptide 9  3,82   3,80   2,40 
Heat shock-related 70 kDa protein 2 N N   N    
Collagen alpha-1(XIV) chain 13,66 71,42   13,23    
Cysteine and glycine-rich protein 1 4,02 8,48   15,93    
Myosin-9  11,12 6,22  8,84    
Annexin A6;Annexin N N N  N    
Histone H1.2 67,20 44,48   29,03 35,70  20,30 
Desmin  2,52  0,00 3,34 0,00 0,00  
Filamin-A  1,85   3,76 0,00 0,00  
Glutathione S-transferase P 12,94 18,68   24,22    
Collagen alpha-1(XII) chain  4,08  7,06 4,33    
Tubulin beta chain 10,40 10,96   16,79    
Creatine kinase B-type  N   N    
Procollagen C-endopeptidase enhancer 1  N       
Mimecan  1,92 0,00    0,00  
Septin-7;Septin-14  N   N    
Protein disulfide-isomerase A3 8,40 13,29   12,82    
Triosephosphate isomerase  7,40   10,99    
Gelsolin  11,66   10,81    
Thioredoxin domain-containing protein 5  7,83   7,43    
78 kDa glucose-regulated protein  7,17 4,67  7,20    
Heat shock cognate 71 kDa protein 3,75 3,45   2,55    
Protein-glutamine 𝛾-glutamyltransferase 2 N  N      
Cofilin-1 4,80 6,59       
Keratin, type II cytoskeletal 5     N    
Fibulin-1  4,68       
14-3-3 protein zeta/delta  5,28   4,67    
Collagen alpha-3(VI) chain  3,56       
Neuroblast diff.-associated protein AHNAK 5,28 5,04   4,04    
Cytoskeleton-associated protein 4 3,77 6,85   3,97    
Lumican    0,00   0,00  
Decorin    0,00   0,00  
Peroxiredoxin-6  11,09 9,41  11,54    
Protein S100-A11     N    
14-3-3 protein epsilon N        
Moesin N  N      
Myosin regulatory light chain 12A; 12B     N    
Peptidyl-prolyl cis-trans isomerase A  2,11   3,15    
Transgelin    0,00  0,00 0,00  
Transgelin-2     N    
Tropomyosin alpha-3 chain     N N   
Vimentin    0,00   0,01  
Calmodulin    8,43 4,81    
Pyruvate kinase PKM;Pyruvate kinase 5,07    4,08    
Tubulin beta-4B chain;Tubulin beta-4A chain  2,55   3,20    
Pigment epithelium-derived factor  4,23   6,41    
Alpha-actinin-4  4,12   5,61    
Phosphoglycerate kinase 1  6,26   5,57    
Collagen alpha-1(V) chain     N    
Collagen alpha-1(VI) chain  2,41       
Collagen alpha-2(VI) chain  3,16       
PDZ and LIM domain protein 7     N    
Myosin light chain kinase, smooth muscle     N    




3.7.3 Gene Ontology (GO) 
The obtained differentially expressed proteins were subjected to GO classification 
via the PANTHER Classification System database (http://www.pantherdb.org/). 
PANTHER is a comprehensive system that combines gene function, ontology, 
pathways and statistical analysis tools, enabling to analyze large-scale, genome-
wide data from sequencing, proteomics or gene expression experiments. It is widely 
used by bench scientists, bioinformaticians, computer scientists and systems 
biologists (Mi et al., 2013). The proteins identified in this study were classified 
according to the 3 GO terms (molecular function, cellular component and biological 
process) and to PANTHER pathways. According to molecular function, most of the 
differently expressed proteins showed structural molecule activity (38.8%), 
followed by binding (31.0%) and catalytic activity (27.6%) (Figure 3.7).  
 
 
Figure 3.7. Classification of proteins according to molecular function (www.pantherdb.org/). 
These proteins were then classified according to their cellular localization. Cellular 
components were mainly distributed in cell (40.5%) and organelle (31.9%) 
structures, but they displayed scattering into cell junction (6.0%), membrane 
(6.0%), macromolecular complex (5.2%), extracellular region (5.2%) and 





Figure 3.8. Classification of proteins according to cellular localization (www.pantherdb.org/). 
In addition, the proteins were also analyzed according to PANTHER pathway 
database. Pathway analysis revealed that many of the proteins detected participate 
in: cytoskeletal regulation (15.8%), inflammation mediated by chemokine and 
cytokine signaling pathway (13.7%), integrin signaling pathway (9.5%), nicotinic 
acetylcholine receptor signaling pathway (7.4%), Parkinson (6.3%) and Huntington 













Biological process classification revealed that most of the differentially expressed  
proteins were involved in cellular processes (30.0%), cellular component 
organization or biogenesis (19.5%), metabolic processes (13.6%), multicellular 
organismal processes (10.0%) and developmental processes (8.6%) (Figure 3.10). 
 
Figure 3.10. Classification of proteins according to biological process (www.pantherdb.org/). 
Moreover, the proteins involved in developmental processes were identified and 
reported in Table 3.11. 
Table 3.11. Main proteins involved in developmental processes. 
Protein name Gene 
Mimecan OGN 
Myosin regulatory light chain 12A MYL12A 
Myosin-3 MYH3 
Myosin-11 MYH11 
Collagen alpha-1(V) chain COL5A1 
PDZ and LIM domain protein 7 PDLIM7 
Tropomyosin beta chain TPM2 
Procollagen C-endopeptidase enhancer 1 PCOLCE 
Fibulin-1 FBLN1 
Myosin-7 MYH7 
Cysteine and glycine-rich protein 1 CSRP1 







Collagen alpha-1(VI) chain COL6A1 
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Developmental process (GO:0032502) was further investigated and sub-classified 
(Figure 3.11). The two most represented classes of proteins were  system (34.3%) 
and mesoderm (34.3%) development proteins. Also proteins involved in the 
ectoderm development were present (17.1%). Proteins involved in the cell 
differentiation (8.6%) and in the anatomical structure morphogenesis (5.7%) were 
also observed. 
 
Figure 3.11. Classification of proteins according to developmental process (www.pantherdb.org/). 
 
Finally, the proteins were annotated according to system development 
(GO:0048731) (Figure 3.12). In this category, most of the proteins were those 
involved in the muscle organ development (44.4%). The next biggest group 
contains proteins involved in the nervous system development (27.8%). There were 
also some proteins which participate in the development of the heart (11.1%), of the 




Figure 3.12. Classification of proteins according to system development (www.pantherdb.org/). 
 
The proteins annotated as involved in system development were reported in Table 
3.12. 
Table 3.12. Main proteins involved in system development. 
Protein name Gene System development 
Myosin-11 MYH11 muscle organ 
PDZ and LIM domain protein 7 PDLIM7 muscle organ, heart, skeletal system 
Myosin-7 MYH7 muscle organ 
Cysteine and glycine-rich protein 1 CSRP1 muscle organ 
Tropomyosin alpha-3 chain TPM3 muscle organ, nervous system 
Myosin-7B MYH7B muscle organ 
Myosin-6 MYH6 muscle organ 
Myosin-9 MYH9 muscle organ 
Mimecan OGN nervous system 
Procollagen C-endopeptidase enhancer 1 PCOLCE 
nervous system, heart, skeletal system, 
angiogenesis 
Lumican LUM nervous system 
Prolargin PRELP nervous system 
 
We investigated the proteins involved in system development in the umbilical cords 
affected by malformations of the nervous system: CC1(15) (Neural tube defect – 
multiple), CC5(15) (Neural tube defect), CC9(15) (Neural tube defect, congenital 
heart disease, cleft lip and palate), G11 (Neural tube defect) (Table 3.13). 




Table 3.13. Differentially expressed proteins in the samples affected by malformations of the 
nervous system.     








Myosin-11 muscle organ   3,27 3,53 0,00 
Cysteine and glycine-rich 
protein 1 muscle organ 4,02 8,48 15,93   
Myosin-9 muscle organ   11,12 8,84   
Procollagen C-endopeptidase 
enhancer 1 
nervous system, heart, skeletal 
system, angiogenesis   N     
Mimecan nervous system   1,92   0,00 
Lumican nervous system       0,00 
Tropomyosin alpha-3 chain muscle organ, nervous system     N   
PDZ and LIM domain protein 7 muscle organ, heart, skeletal system     N   
 
The differentially expressed proteins identified in the umbilical cords affected by 
trisomy 21 (TRIS21) were classified according to the 3 GO terms (molecular 
function, cellular component and biological process). According to molecular 
function, the majority of the proteins showed binding activity (42.3%), followed by 
catalytic activity (33.3%) and structural molecule activity (19.2%) (Figure 3.13). 
  





The differentially expressed proteins identified in TRIS21 were then classified 
according to their cellular localization. Cellular components were mainly 
distributed in cell (37.7%) and organelle (20.8%) structures, but they displayed 
scattering into cell junction (13.2%), membrane (13.2%), extracellular region 
(7.5%) and extracellular matrix (7.5%) (Figure 3.14). 
  
Figure 3.14. Classification of proteins identified in TRIS21 according to cellular localization 
(www.pantherdb.org/). 
 
Biological process classification of the differentially expressed proteins identified 
in TRIS21 revealed that the most proteins were involved in cellular processes 
(23.2%), metabolic processes (22.1%), cellular component organization or 
biogenesis (17.7%), multicellular organismal processes (9.4%) and developmental 




Figure 3.15. Classification of proteins identified in TRIS21 according to biological process 
(www.pantherdb.org/). 
 
The differentially expressed proteins identified in the umbilical cord CC35 
(Congenital heart disease) were classified according to the 3 GO terms.  
According to molecular function, the most proteins showed structural molecule 
activity (36.6%), followed by binding activity (32.4%) and catalytic activity 
(25.4%) (Figure 3.16). 
  




The differentially expressed proteins identified in CC35 were then classified 
according to their cellular localization. Cellular components were mainly 
distributed in cell (34.6%) and organelle (29.5%) structures, but they displayed also 
cell junction (9.0%), membrane (9.0%), extracellular region (7.7%), 
macromolecular complex (5.1%) and extracellular matrix (5.1%) (Figure 3.17). 
  
Figure 3.17. Classification of proteins identified in CC35 according to cellular localization 
(www.pantherdb.org/). 
 
The proteins identified in CC35 were then classified according to their biological 
process. Biological process classification revealed that the most proteins were 
involved in cellular processes (24.6%), cellular component organization or 
biogenesis (16.4%), multicellular organismal processes (11.9%), localization 





Figure 3.18. Classification of proteins identified in CC35 according to biological process 
(www.pantherdb.org/). 
Finally, the differentially expressed proteins identified in the umbilical cord 
CC7(15) (malformation of the gastrointestinal system) were classified according to 
the 3 GO terms.  
According to molecular function, the most proteins showed catalytic activity 
(35.0%), followed by structural molecule activity (30.0%), binding activity 
(20.0%), receptor (10.0%) and antioxidant activity (5.0%) (Figure 3.19). 
 




The differentially expressed proteins identified in CC7(15) were then classified 
according to their cellular localization. Cellular components were mainly 
distributed in cell (31.8%), organelle structures (22.7%), extracellular matrix 
(18.2%), extracellular region (18.2%), but they displayed also cell junction (4.5%), 
and membrane (4.5%) (Figure 3.20). 
 
 Figure 3.20. Classification of proteins identified in CC7(15) according to cellular localization 
(www.pantherdb.org/). 
 
Biological process classification of the differentially expressed proteins identified 
in CC7(15) revealed that the most proteins were involved in cellular processes 
(19.0%), metabolic processes (16.7%), multicellular organismal processes (16.7%), 
cellular component organization or biogenesis (14.3%), developmental (11.9%) and 




Figure 3.21. Classification of proteins identified in CC7(15) according to biological process 
(www.pantherdb.org/). 
 
3.8 Gelatin zymography 
MMPs have been shown to play significant roles in different physiological 
processes, including embryogenesis and angiogenesis, but also contribute to 
pathological processes such as tumor metastasis, inflammation and arthritis (Kupai 
et al., 2010). Of this diverse family of enzymes, the gelatinases MMP-2 (gelatinase 
A) and MMP-9 (gelatinase B) have been extensively studied owing to their 
consistent association with tumor invasion and metastasis (Toth and Fridman, 
2001). It has been reported that MMP-2 and MMP-9 functional gene 
polymorphisms might be associated with an increased risk of idiopathic recurrent 
spontaneous abortion (IRSA) in women (Pereza et al., 2012). Gelatin zymography 
was performed for the detection and analysis of the level and type of the gelatinases 
MMP-2 and MMP-9 expressed in umbilical cords. Thus extracts of umbilical cords 
from malformed fetuses and from a healthy one with similar gestational age as 
control showed two major bands in zymograms: MMP-2 (72 kDa) and MMP-9 (92 






Figure 3.22. Representative gelatin zymograms showing MMP-9 and MMP-2 activities in extracts 
of umbilical cords from malformed fetuses. 
 
Our results showed a significantly increased activity of MMP-2 in CC8(15) 
(Klinefelter syndrome) and in CC7(15) (malformation of the gastrointestinal 
system) compared to control. The activity of MMP-2 was significantly lower in G2 
[Dyssegmental dysplasia, Silverman-Handmaker type (DDSH)], CC9(15) 
(Congenital heart disease, cleft lip and palate, neural tube defect), CC10 (Trisomy 
21), G16 (Klinefelter syndrome), CC1(15) (Neural tube defect – multiple), CC32 
(Non-immune hydrops), CC35 (Congenital heart disease) (**p < 0.001) (Figure 
3.23). However, no significant differences in MMP-2 levels were observed in the 
other malformed samples [G1, G3, CC31, G6, CC5(15)].  
In order to verify the observed gelatinolytic activity of MMP-2, we performed a 
Western blotting analysis, but no significant variation of MMP-2 levels was 
observed. Based on zymography results, we performed a more MS analysis of our 
proteomic data aimed to investigate a possible difference of MMP-2 expression, but 
no significant difference was highlighted in CC8(15). 
Indeed, zymography measures the proteolytic activity, not expression levels, of 
MMPs (Keles et al., 2014). MMP protein levels do not directly reflect MMP 
activity as only the inactive form of the protein may be present, or an excess of an 
inhibitor may block activity (Lowrey et al., 2008). 
So it's not surprising that we have not found an up or downregulation of MMPs in 
proteomic data. Although a significant difference of MMP-2 was not observed in 
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proteomic data, the analysis of the differentially expressed proteins in CC8(15) 
showed some correlations with MMP-2. 
MMP-2 is constitutively expressed on the amnion during gestation in several 
animal species, including humans. The activity of MMP-2 is enhanced during 
labour (Vadillo-Ortega and Estrada-Gutiérrez, 2005). An appropriate level of 
MMP-2 is needed for normal pregnancy (Zhang et al., 2003). It is involved in cell 
invasion and in embryonic development and organogenesis. A growing number of 
reports suggest that MMP-2 is involved in renal development, renal tubule 
physiology and glomerular pathophysiology (Lelongt et al., 2001). MMP-2 is 
expressed in neurons and glia, supporting a primary role in embryonic neuronal 
development (Miller et al., 2008). MMP-2 appears to have a crucial role in 
embryonic heart development including angiogenesis, valve development, and heart 
tube formation. Inhibition of MMP-2 causes severe heart tube defects, cardia bifida, 
and a disruption in the looping direction, which suggest a key role of MMP-2 in cell 
migration and remodeling required for normal heart development (Youssef and 
Schulz, 2011). MMP-2 plays also a direct role in early skeletal development and 
bone cell growth and proliferation. Its loss results in decreased bone mineralization, 
joint erosion and defects in osteoblast and osteoclast growth (Mosig et al., 2007). 
By studying the proteins differentially expressed in CC8(15), we could highlight 
that their up or downregulation may have been influenced by the activity of MMP-
2. Decorin, that was absent in CC8(15), is a ubiquitous proteoglycan comprised of a 
core protein attached to a single dermatan/chondroitin sulphate glycosaminoglycan 
chain. It may play a role in regulation of collagen fibrillogenesis and function as a 
reservoir of transforming growth factor beta (TGF-beta) in the extracellular milieu. 
It was demonstrated that decorin is susceptible to many MMPs and is degraded by 
MMP-2 (Imai et al., 1997). 
Desmin [absent in CC8(15)], is a muscle-specific, type III intermediate filament 
that integrates the sarcolemma, Z disk, and nuclear membrane in sarcomeres and 
regulates sarcomere architecture (Sequeira et al., 2014). It was found that desmin is 
susceptible to degradation by MMP-2 in vitro (Kandasamy et al., 2010).  
Calmodulin, that was upregulated in CC8(15), is a small Ca
2+
-binding protein and 
acts in signal transduction in cell growth, differentiation, proliferation, survival, and 
motility through association with calmodulin-binding proteins (Agell et al., 1998). 
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Binding of calmodulin to K-Ras4B-GTP activates the PI3K/Akt (also known as 
protein kinase B, PKB) pathway and enhances cell migration through inducing the 
expression of MMP-2 which breaks down type IV collagen, a major structural 




Figure 3.23. Zymographic MMP-2 levels in umbilical cords. Densitometric ratio in Ctrl was 
arbitrarily indicated as equal to the unit and represented as mean values ± SD of three separate 
experiments (**p < 0.001). 
 
Zymography showed significantly higher levels of MMP-9 in G2 (DDSH) and in 
CC7(15) (malformation of the gastrointestinal system) than in control (**p < 0.001) 
(Figure 3.24). However, there were no significant differences in MMP-9 levels for 
the other samples of malformed fetuses (data not shown). 
DDSH is a lethal autosomal recessive form of dwarfism with characteristic 
anisospondylic micromelia and is caused by functional null mutations of the 
perlecan gene (HSPG2) (Arikawa-Hirasawa et al., 2001). Perlecan is a heparan 
sulfate proteoglycan expressed in basement membranes and cartilage. It in cartilage 
plays a critical role in endochondral bone formation by promoting angiogenesis 
essential for cartilage matrix remodeling and subsequent endochondral bone 
formation. In the absence of perlecan, chondrocytes were able to differentiate into 
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mature hypertrophic chondrocytes. MMP-9 is expressed in the hypertrophic 
chondrocytes of wild-type mice and Hspg2
−/−
 mice and is involved in degradation 
of the hypertrophic matrix (Ishijima et al., 2012). 
The umbilical cord CC7(15) is affected by a malformation of the gastrointestinal 
system. Recent studies have implicated a pathogenic role for MMP-9 in 
inflammatory bowel disease (IBD) (Nighot et al., 2015). It has been shown that 
epithelial-derived MMP-9 is crucial in intestinal damage (Castaneda et al., 2005). 
Indeed, epithelial-derived MMP-9 is absent in normal colonic tissue but is 
upregulated during IBD and could be responsible for degradation of extracellular 
matrix (ECM) components with subsequent loss of mucosal integrity and increase 




Figure 3.24. Zymographic MMP-9 levels in umbilical cords. Densitometric ratio in Ctrl was 
arbitrarily indicated as equal to the unit and represented as mean values ± SD of three separate 
experiments (**p < 0.001). 
 
 
All these assessments will require further confirmation based on the analysis of a 




3.9 Western blotting analysis 
In order to verify the observed gelatinolytic activity on zymography of MMP-2 and 
MMP-9, we analyzed the protein levels through Western blotting. No significant 
variation of MMP-2 levels was observed. Instead, both zymography and Western 
blotting analysis showed that MMP-9 was significantly increased in G2 and in 
CC7(15) (Figure 3.25). 
 
 
Figure 3.25. MMP-9  levels in umbilical cords. GAPDH was used as loading control. Blots shown 
are from one experiment representative  of at least two with similar results. 
 
3.10 Metal analyses in mother’s hair and umbilical cords 
The analyses were performed, with a standard protocol, at the Laboratories of the 
Maugeri Foundation (Pavia, Italy), and Prof. Stefania Papa , Seconda Università di 
Napoli and included additional seven samples of hair with already known metal 
load, as technical controls. Unfortunately, it is currently not available a 
international  standard for the heavy metals in  umbilical cords, based on samples 
with already known metal load. Briefly, hair and umbilical cord samples were 
weighed and mineralized in a microwave oven in 65% HNO3 (3.5 mL) + 30% 
H2O2 (0.5 mL, Suprapur-Merck), diluted 1:20 in bidistilled H2O and analyzed in 
DRC-ICP-MS with 20 sweeps/reading. The DRC-ICP-MS instrument was an 
ELAN DRC ІІ (Perkin Elmer, SCIEX Instruments, Toronto, ON, Canada) with a 
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quadrupolar analyzer, mass interval 5-270 amu, source ICP, radiofrequency 40 
MHz, max. power 1,600 W. Analysis of metal load by DRC-ICP/MS were run for 
Li, Be, Co, Zn, Hg, Cd, Ba, V, Mn, Sn, Sb, Ti, Ce, Rb, Pb, W, Tl, As, Ni, Se, V, Cr, 
Cu, U, Mg, K. Limits of detection (LOD) varied from 0.01 for Se, to 0.0004 for U. 
Our results showed significantly increased levels of Sn, Ti, and W in mother’s hair. 
The umbilical cords seem to show significantly increased levels of Ti (Appendix 
B). It was suggested that metal-based particles containing Ti penetrate into the 
amniotic fluid and may affect human fetuses (Barošová et al., 2015). 
Because of the small number of samples analyzed and the absence of an 























It is known by studies conducted in the Gaza Strip and in Iraq that prenatal 
exposure to pollutants and particularly heavy metals can have long term damaging 
consequences on infants, due to their accumulation in-body. Thus, direct exposure 
to waste and heavy metals during the last two decades was very frequent in the so-
called “Land of fires”. The number of children suffering from cancer and of 
malformed fetuses in Italy's "Land of Fires", an area where toxic waste has been 
dumped by the mafia, is reported significantly higher than elsewhere in the country. 
In this thesis we examined the proteome of the umbilical cords from malformed 
fetuses obtained by therapeutic abortions, after mothers' being exposed to the 
pollution on “land of fires” during early pregnancy, and analyzed the differences 
between umbilical cords from malformed fetuses to healthy ones. The main goals 
were to understand the impact of the contamination by heavy metals on the fetus 
development, and to identify new putative biomarkers of exposure to metal 
contaminants.  
The proteomic study of heterogeneous tissue samples as the umbilical cord was 
performed by the FASP technique. This bio-analytical strategy combines the 
advantages of in-gel and in-solution digestion for mass spectrometry–based 
proteomics, greatly reduced the time required for sample preparation and enabled 
more flexibility in sample processing. 
Many differentially expressed proteins were identified. By a Gene Ontology (GO) 
study it was possible to obtain functional informations of these proteins and to 
correlate them to the embryonic development. Most of the differently expressed 
proteins showed structural molecule activity. 
Gelatin zymography was set up and performed for the detection and analysis of the 
levels of the gelatinases MMP-2 and MMP-9 expressed in the umbilical cords. A 
different activity of these MMPs in the malformed umbilical cords was assessed. In 
particular, the increased activity observed for MMP-2 may be related to some 
proteins, such as decorin, desmin, and calmodulin, that were differentially 
expressed in samples where MMP-2 showed increased activity. Our results could 
support a significant role of the MMPs in the fetus development. 
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This was a pilot project still in progress. However, our preliminary results support 
the hypothesis that heavy metals alter proteome expression and can induce 
significant changes in proteomic profiles of the exposed organisms. This work 
demonstrates and confirms the importance of proteomics to assess the biochemical 
changes and to elucidate the underlying mechanisms of toxicity induced by heavy 
metals in malformed fetuses. Additional studies, including collection of umbilical 
cords from malformed fetuses and from healthy ones as controls, genomic and 
transcriptomic analyses, are in progress to identify new protein pathways involved 
in heavy metal toxicity and to discover novel biomarkers. 
Although all obstacles expected and not expected that sometimes made us think of 
a boycott, we hope that our project will continue and that the situation in the “land 
of fires” will become an important objective for scientific community, politics, and 
society.  
“Nella Terra dei Fuochi i bambini continuano a morire. Negli ultimi venti giorni 
sono otto i bambini morti di tumore. Questi bambini non riposeranno mai in pace. 
Per loro non c'è giustizia”. Avevano tutti tra i sette mesi e gli undici anni. È il grido 
di denuncia delle mamme aderenti al comitato “Vittime della terra dei fuochi” del 6 
Febbraio scorso. 
“In the Land of Fires children continue to die. In the last twenty days eight children 
died of cancer. These children never rest in peace. For them there is no justice”. 
They all had between seven months and eleven years. It is the cry of complaint of 
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Nome del medico in servizio 
 
Nome di infermiera in servizio 
 
Numero file x RICERCA: 
 
Numero tessera sanitaria madre: 
 
Il questionario contiene le informazioni sul bambino (B), il padre (P) e la madre (M): 
 
Data di intervento 





Luogo di residenza della famiglia : 
Strada 
Riferimento Telefonico 
Relazione tra i genitori: 1 - cugini [] 2 - dalla famiglia [] 3 - nessuna parentela [] 
Sesso del bambino 1 - Maschio [] 2 - Femmina [] 
Questo bambino: 1 - Singolo[] 2 - Gemelli [] 
Ordine di nascita del neonato 
 
Dati clinici 
Le informazioni qui di seguito devono essere raccolte dal personale medico responsabile 
Settimane di gestazione (numero) 
Peso alla nascita  in grammi 
Tipo di malformazione: 
1 - Difetto cardiaco congenito, CHD [] Q20-Q28, specifica 
 
2 - Labbro / palatoschisi, CL / P []Q35-Q37, specifica 
 
3- Difetti agli arti []Q65-Q79 , specifica 
 
4 - Difetto sistema nervoso [],Q00-Q07 specifica 
 
5- Difetto sistema digerente []Q38-Q45, specifica 
 
6- Difetto muscolo scheletrico  []Q65-Q79, specifica 
 
7- Difetto sistema respiratorio [] Q30-Q34, specifica 
 
8-Difetto sistema urinario []Q60-Q64, specifica 
 
9-Difetto sistema genitale [Q50-Q56, specifica 
 
10 -Malformazioni multiple [] specifica 
 
11-Difetti occhio, orecchio, collo  e viso [] Q10-Q18, specifica 
 
12 – Altre  [] Q80-Q89, specifica 
 








Campioni prelevati da, iniziali operatore  
Capelli madre [] 
Cordone [] 
Placenta [] 









Inizia l'intervista dicendo al genitore che stiamo iniziando un programma di studio sulle malformazioni congenite e 
chiediamo la collaborazione per poter investigare i motivi e le alterazioni biologiche coinvolte. 
Perciò useremo in modo anonimo le informazioni che ci daranno e i materiali che raccogliamo: cordone ombelicale, 
placenta e un ciuffetto di capelli della madre.  
 
Tutti i dati forniti saranno trattati con la massima riservatezza e soltanto da personale sanitario e di ricerca per scopi 
scientifici e clinici. I nomi delle persone che collaborano non potranno mai essere resi noti nè i loro indirizzi e 
telefoni.  
 
Lei è d'accordo di rispondere? 
Firma per consenso di Madre: _____________________________________________ 
e (facoltativa) 










2. -Lavoro attuale: __________________ Passato: ___________________ attività lavorative di rischio*__________ 
 
Per la madre:  
1. Prima gravidanza ? [] 
 
 
Quante gravidanze/ figli ha avuto? 
Data di nascita-mese anno        
Sesso        
Sano        
Con malformazione + tipo        
Interruzione gravidanza +causa        
Nato morto        
Figli con tumori +tipo        
Figlio con malattia cronica +tipo        
Aborti spontanei + settimana di gestazione 
+ aveva malformazioni? 
       
 
Durante la gravidanza, ha preso FARMACI  []  se si quali e in che dosi _____________________________ 
 
Durante la gravidanza, ha preso VITAMINE  []  se si quali e in che dosi ____________________________ 
 
Durante la gravidanza, ha preso acido folico []  se si quali e in che dosi ____________________________ 
 
Durante la gravidanza   o prima ha usato Trattamenti estetici [] e quali (tinture, creme con acido retinoico..ecc) 
_______________________   
 
DIETA : Nessuna particolarità  [] vegetariana  []  senza-molto poco latte []  senza-molto poco latticini []    senza-molto 
poco pesce []  senza-molto poco verdure [].  
 
Per la madre ed il padre 







Siete fumatori? _____________ quante sigarette al giorno? ____________ 
Siete esposti a sostanze tossiche sul luogo di lavoro? Se si, quali? 
Usate /avete usato negli ultimi 10 anni o usano i vostri vicini:   
pesticidi / insetticidi / fertilizzanti e altri prodotti chimici per la coltivazione della terra? 
Se si, quali? 
 
Nelle adiacenze  della casa attuale si trova: 
Discarica di immondizia Sì [] o No [], distanza………………….., data di apertura…………… 
 
Inceneritore Sì [] o No [],distanza………………….., data di apertura…………… 
 
Luoghi dove si brucia immondizia all’aperto? Sì [] o No [],distanza………………….., data di apertura…………… 
 
Fabbrica, Sì [] o No [], specifica tipo di produzione…………, distanza………………….., data di apertura…………… 
 
Strada di alto traffico Sì [] o No [],distanza………………….., data di apertura…………… 
  
Quando è stata costruita la casa attuale? 
Da quanto tempo vive nella attuale residenza? 
Dove abitava prima, negli ultimi 10 anni? 
Quando era stata costruita la precedente residenza? 
 
Che acqua usa per bere/cucinare? 
 
Avete lavorato/lavorate nel settore di scavi e /o dei materiali da costruzione? 
Sì [] o No [], 
Se sì, quando e per quanto a lungo e con che ruolo 
 
Dal momento che avete avuto un bambino con difetti alla nascita, vorremmo esaminare le possibili cause e se ci sono 
altri casi nella famiglia estesa. Apprezziamo la vostra risposta alle seguenti domande. 
 
 Madre Padre 
Soffre di malattie? quali   
Un genitore ha malformazioni?   
Uno zio/zia ha malformazioni?   
Cugini o cugine con malformazioni?   
Quanti fratelli ha?   
Quante sorelle ha?   
Sono tutti in salute i fratelli?   
Se qualcuno ha una malformazione, di che 
tipo? 
  
Sono tutti in salute le sorelle?   
Se qualcuna ha una malformazione, di che 
tipo? 
  
Quanti figli hanno i fratelli?   
Sono tutti in salute i figli dei fratelli?   
Se qualcuno ha una malformazione, di che 
tipo? 
  
Quanti figli hanno le sorelle?   
Sono tutti in salute i figli delle sorelle?   
Se qualcuno ha una malformazione, di che 
tipo? 
  
Qualcuno dei fratelli o sorelle abita vicino 
a voi? 
  
Se possibile, allegare UN'IMMAGINE (o un riferimento a un file di immagini) delle pertinenti caratteristiche 
morfologiche. 
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